摘要
目的探讨左旋多巴联合恩他卡朋对帕金森病患者血清白细胞介素-1β(IL-1β)、胱抑素-C(Cys-C)的影响。方法选择2014年6月~2016年6月我院接诊的90例帕金森病患者,通过随机数表法分为观察组和对照组各45例。对照组使用左旋多巴治疗,观察组在此基础上,联用恩他卡朋治疗。比较两组IL-1β、Cys-C、UPSRS评分、H-Y分期、生活质量(PDQ-39)、临床疗效及不良反应。结果治疗后,观察组IL-1β、Cys-C水平低于对照组(P<0.05);观察组UPSRS评分、H-Y分期、生活质量PDQ-39评分低于对照组低(P<0.05);观察组临床疗效总有效率95.56%(43/45)高于对照组66.67%(30/45)(P<0.05);观察组不良反应总发生率17.78%(8/45)低于对照40.00%(18/45)(P<0.05)。结论在帕金森病患者中应用左旋多巴联合恩他卡朋治疗效果显著,可有效改善运动功能和生活质量,提高临床疗效,其机制可能和降低血清IL-1β、Cys-C水平相关,且联合用药可缓解左旋多巴产生的不良反应,安全性高,值得应用推广。
Objective To study effect of levodopa combined with entacapone on serum interleukin （IL）-10 and Cystatin（Cys）-C in patients with Parkinson＇s disease. Methods 90 patients of parkinson＇s disease received therapy from June 2014 to June 2016 in our hospital were selected. According to random number table, those patients were divided into the observation group （n=45） and the control group （n=45）. The control group was treated with levodopa, while the ob- servation group was treated with entacapone. The IL-1β, Cys-C, UPSRS score, H-Y staging, quality of life（PDQ-39）, clinical efficacy and adverse reaction were compared. Results After treatment, the levels of IL-1β and Cys-C in the observation group were lower than that of the control group[ （9.84±1.74）pg/ml vs（ 13.04 ±2.13）pg/ml, （1.05±0.21） mg/L vs（1.21 ± 0.25）mg/L] （P〈0.05）. The UPSRS score, H-Y staging and quality of life PDQ-39 score of observation group was lower than that of the control group[（8.14 ± 1.73） score vs（11. 79 ± 1.84） score, （1.33 ± 0.17） vs（1.64 ± 0.24） ,（30. 28 ±4.15）score vs（42.03 ± 5.65）score] （P〈0.05）. The total effective rate of the observation group was higher than that of the control group[95.56 % （43/45）vs66.67 % （30/45）] （P〈0.05）. The incidence of adverse reactions in observation group was lower than that of the control group [-17.78% （8/45）vs40.00% （18/45）] （P〈0.05）. Conclusion Levodopa is effective for parkinson＇s disease, which can improve the motor function and quality of life, improve clinical efficacy. The mechanism may be related to the decrease of serum IL-1 and Cys-C,. The combined treatment can alleviate the adverse reaction of levodopa and get high safety.
出处
《西部医学》
2017年第6期791-794,共4页
Medical Journal of West China
